DTILPrecision Biosciences Inc
DTIL
Precision Biosciences Inc3,729
Mkt Cap
$181.65MVolume
41,362.0052W High
$8.8252W Low
$3.53PE Ratio
-1.36DTIL Fundamentals
Price
$7.03Prev Close
$7.04Open
$7.1750D MA
$5.80Beta
0.72Avg. Volume
374,032.98EPS (Annual)
-$3.63P/B
1.84Rev/Employee
$503,882.35$33.42
Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that new preclinical data from its PBGENE-DMD program have been accepted for an...
Business Wire·6h ago
AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains?
AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·1d ago
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need...
Business Wire·4d ago
Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will present new clinical biopsy data from the ongoing Phase 1 ELIMINATE-B...
Business Wire·6d ago
Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?
Cartesian Therapeutics, Inc. (RNAC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·8d ago
Short Interest in Precision BioSciences, Inc. (NASDAQ:DTIL) Decreases By 16.2%
Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) saw a significant decline in short interest in March. As of March 31st, there was short interest totaling 1,171,027 shares, a decline of...
MarketBeat·11d ago
JonesTrading Reiterates Buy Rating for Precision BioSciences (NASDAQ:DTIL)
JonesTrading restated a "buy" rating and issued a $30.00 price objective on shares of Precision BioSciences in a research note on Friday...
MarketBeat·11d ago
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has received Clinical Trial Application (CTA) approval to expand the...
Business Wire·13d ago
Should You Buy Precision BioSciences (DTIL) After Golden Cross?
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Zacks·14d ago
Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need...
Business Wire·20d ago
<
1
2
...
>